Report Detail
Global Anti Obesity Drugs Market Insights, Forecast to 2025
- RnM3329580 |
- 19 April, 2019 |
- Global |
- 123 Pages |
- QYResearch |
- Pharma & Healthcare
The global Anti Obesity Drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Anti Obesity Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Anti Obesity Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Anti Obesity Drugs in these regions.
This research report categorizes the global Anti Obesity Drugs market by top players/brands, region, type and end user. This report also studies the global Anti Obesity Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer
Merck
Roche
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Novo Nordisk
Eisai
Norgine
Arena Pharmaceuticals
Orexigen Therapeutics
Vivus
Alizyme
Rhythm Pharmaceuticals
Shionogi
Zafgan
Market size by Product
Oral Medicine
Diet Patch
Diet Tea
Market size by End User
Men
Women
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Anti Obesity Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Anti Obesity Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Anti Obesity Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Anti Obesity Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Anti Obesity Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Anti Obesity Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Anti Obesity Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Anti Obesity Drugs Market Size Growth Rate by Product
- 1.4.2 Oral Medicine
- 1.4.3 Diet Patch
- 1.4.4 Diet Tea
- 1.5 Market by End User
- 1.5.1 Global Anti Obesity Drugs Market Size Growth Rate by End User
- 1.5.2 Men
- 1.5.3 Women
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Anti Obesity Drugs Market Size
- 2.1.1 Global Anti Obesity Drugs Revenue 2014-2025
- 2.1.2 Global Anti Obesity Drugs Sales 2014-2025
- 2.2 Anti Obesity Drugs Growth Rate by Regions
- 2.2.1 Global Anti Obesity Drugs Sales by Regions
- 2.2.2 Global Anti Obesity Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Anti Obesity Drugs Sales by Manufacturers
- 3.1.1 Anti Obesity Drugs Sales by Manufacturers
- 3.1.2 Anti Obesity Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Anti Obesity Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Anti Obesity Drugs Revenue by Manufacturers
- 3.2.1 Anti Obesity Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Anti Obesity Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Anti Obesity Drugs Price by Manufacturers
- 3.4 Anti Obesity Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Anti Obesity Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Anti Obesity Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Anti Obesity Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Anti Obesity Drugs Sales by Product
- 4.2 Global Anti Obesity Drugs Revenue by Product
- 4.3 Anti Obesity Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Anti Obesity Drugs Breakdown Data by End User
6 North America
- 6.1 North America Anti Obesity Drugs by Countries
- 6.1.1 North America Anti Obesity Drugs Sales by Countries
- 6.1.2 North America Anti Obesity Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Anti Obesity Drugs by Product
- 6.3 North America Anti Obesity Drugs by End User
7 Europe
- 7.1 Europe Anti Obesity Drugs by Countries
- 7.1.1 Europe Anti Obesity Drugs Sales by Countries
- 7.1.2 Europe Anti Obesity Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Anti Obesity Drugs by Product
- 7.3 Europe Anti Obesity Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Anti Obesity Drugs by Countries
- 8.1.1 Asia Pacific Anti Obesity Drugs Sales by Countries
- 8.1.2 Asia Pacific Anti Obesity Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Anti Obesity Drugs by Product
- 8.3 Asia Pacific Anti Obesity Drugs by End User
9 Central & South America
- 9.1 Central & South America Anti Obesity Drugs by Countries
- 9.1.1 Central & South America Anti Obesity Drugs Sales by Countries
- 9.1.2 Central & South America Anti Obesity Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Anti Obesity Drugs by Product
- 9.3 Central & South America Anti Obesity Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Anti Obesity Drugs by Countries
- 10.1.1 Middle East and Africa Anti Obesity Drugs Sales by Countries
- 10.1.2 Middle East and Africa Anti Obesity Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Anti Obesity Drugs by Product
- 10.3 Middle East and Africa Anti Obesity Drugs by End User
11 Company Profiles
- 11.1 Pfizer
- 11.1.1 Pfizer Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Pfizer Anti Obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Pfizer Anti Obesity Drugs Products Offered
- 11.1.5 Pfizer Recent Development
- 11.2 Merck
- 11.2.1 Merck Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Merck Anti Obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Merck Anti Obesity Drugs Products Offered
- 11.2.5 Merck Recent Development
- 11.3 Roche
- 11.3.1 Roche Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Roche Anti Obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Roche Anti Obesity Drugs Products Offered
- 11.3.5 Roche Recent Development
- 11.4 GlaxoSmithKline
- 11.4.1 GlaxoSmithKline Company Details
- 11.4.2 Company Business Overview
- 11.4.3 GlaxoSmithKline Anti Obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 GlaxoSmithKline Anti Obesity Drugs Products Offered
- 11.4.5 GlaxoSmithKline Recent Development
- 11.5 AstraZeneca
- 11.5.1 AstraZeneca Company Details
- 11.5.2 Company Business Overview
- 11.5.3 AstraZeneca Anti Obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 AstraZeneca Anti Obesity Drugs Products Offered
- 11.5.5 AstraZeneca Recent Development
- 11.6 Boehringer Ingelheim
- 11.6.1 Boehringer Ingelheim Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Boehringer Ingelheim Anti Obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Boehringer Ingelheim Anti Obesity Drugs Products Offered
- 11.6.5 Boehringer Ingelheim Recent Development
- 11.7 Novo Nordisk
- 11.7.1 Novo Nordisk Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Novo Nordisk Anti Obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Novo Nordisk Anti Obesity Drugs Products Offered
- 11.7.5 Novo Nordisk Recent Development
- 11.8 Eisai
- 11.8.1 Eisai Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Eisai Anti Obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Eisai Anti Obesity Drugs Products Offered
- 11.8.5 Eisai Recent Development
- 11.9 Norgine
- 11.9.1 Norgine Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Norgine Anti Obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Norgine Anti Obesity Drugs Products Offered
- 11.9.5 Norgine Recent Development
- 11.10 Arena Pharmaceuticals
- 11.10.1 Arena Pharmaceuticals Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Arena Pharmaceuticals Anti Obesity Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Arena Pharmaceuticals Anti Obesity Drugs Products Offered
- 11.10.5 Arena Pharmaceuticals Recent Development
- 11.11 Orexigen Therapeutics
- 11.12 Vivus
- 11.13 Alizyme
- 11.14 Rhythm Pharmaceuticals
- 11.15 Shionogi
- 11.16 Zafgan
12 Future Forecast
- 12.1 Anti Obesity Drugs Market Forecast by Regions
- 12.1.1 Global Anti Obesity Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Anti Obesity Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Anti Obesity Drugs Market Forecast by Product
- 12.2.1 Global Anti Obesity Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Anti Obesity Drugs Revenue Forecast by Product 2019-2025
- 12.3 Anti Obesity Drugs Market Forecast by End User
- 12.4 North America Anti Obesity Drugs Forecast
- 12.5 Europe Anti Obesity Drugs Forecast
- 12.6 Asia Pacific Anti Obesity Drugs Forecast
- 12.7 Central & South America Anti Obesity Drugs Forecast
- 12.8 Middle East and Africa Anti Obesity Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Anti Obesity Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Anti Obesity Drugs . Industry analysis & Market Report on Anti Obesity Drugs is a syndicated market report, published as Global Anti Obesity Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Anti Obesity Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
